Back to Search Start Over

High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.

Authors :
Šoić D
Keser T
Štambuk J
Kifer D
Pociot F
Lauc G
Morahan G
Novokmet M
Gornik O
Source :
Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2022 Oct; Vol. 21 (10), pp. 100407. Date of Electronic Publication: 2022 Aug 27.
Publication Year :
2022

Abstract

Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings. The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans. Furthermore, complement system, as well as C3, was previously associated with T1D. It is also known that changes in glycosylation can modulate inflammatory responses, so our aim was to characterize the glycosylation profile of C3 in T1D. For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling. From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled. Significant changes of C3 N-glycan profiles were found. T1D was associated with an increase in the proportion of unprocessed glycan structures with more mannose units. A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879. This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development. Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.<br />Competing Interests: Conflict of interest G. L. is the founder and owner, and M. N. is an employee of Genos Glycoscience Research Laboratory, a company that specializes in high-throughput glycomics and has several patents in this field. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1535-9484
Volume :
21
Issue :
10
Database :
MEDLINE
Journal :
Molecular & cellular proteomics : MCP
Publication Type :
Academic Journal
Accession number :
36031042
Full Text :
https://doi.org/10.1016/j.mcpro.2022.100407